Publications (3)1.22 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the efficacy and side effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer (NSCLC). Sixty-three patients with stage III B and IV NSCLC hospitalized from October 2001 to October 2008 were enrolled and assigned to two groups using a randomizing digital table, with 33 patients in the treatment group and 30 in the control group. They were all treated with the Navelbine and Cisplatin (NP) chemotherapy, but to the treatment group the Chinese drugs Shengmai Injection () by intravenous dripping and Gujin Granule () by oral intake were given additionally. The main observation indexes were response rate (RR), median survival time, 1-year survival rate and median time to progression (TTP); secondary observation indexes were side effects and cycles of chemotherapy. Altogether, 61 patients (33 from the treatment group and 28 from the control group) completed the observation and were assessable. RR was 48.5% (16/33) in the treatment group and 32.2% (9/28) in the control group, and the median survival time were 13 months and 9 months, respectively; the difference between the two groups was significant (P=0.0373 and P=0.014 respectively). However, the differences between groups were insignificant in terms of 1-year survival rate [51.5% (17/33) vs 46.4% (13/28), P=0.4042], median TTP (5.95 months vs 4.64 months, P=0.3242), grade III or IV bone marrow inhibition occurrence rate [33.3% (11/33) vs 39.3% (11/28), P=0.3500], and mean cycles of chemotherapy applied (2.94+/-0.94 cycles vs 2.75+/-0.75 cycles, P=0.4100). Combined Chinese drugs and chemotherapy can enhance the short-term therapeutic efficacy in the treatment of NSCLC and prolong patients' median survival time, but show no evident impact on TTP.
    No preview · Article · Dec 2009 · Chinese Journal of Integrative Medicine
  • Hong Sun · Dong Xue · Fei Gao
    [Show abstract] [Hide abstract]
    ABSTRACT: To observe the effect of Shugan Liangxue Compound (SLC) for relieving hot flashes in breast cancer patients medicated with tamoxifen. A randomized, double blind clinical trial for observing the therapeutic effects of SLC was carried out on 73 breast cancer patients hospitalized from October 2004 to November 2006, who were treated with tamoxifen, and revealed hot flashes. They were randomly assigned to two groups, the 37 in the treated group treated by SLC, and the 36 in the control group treated with placebo. Taking the improvement of hot flashes as an end point index and that of sleep as a secondary index, the effects of treatment were compared by Kupperman scoring with the average times of hot flashes per day and condition of sleep within 1 week before treatment as baseline. The effects on 66 patients (33 in the treated group and 33 in the control group) were evaluable. In the treated group hot flashes disappeared in 5 patients (15.2%), relieved in 14 (42.4%) and unchanged in 14 (42.4%); while in the control group, it disappeared in none, relieved in 10 (30.3%) and unchanged in 23 (69.7%), comparison between groups showed significant difference (P = 0.012). As for the condition of sleep, it was improved in 21 (63.6%) and unchanged in 12 (36.4%) in the treated group; while the condition of sleep in the control group was improved in 13 (39.4%) and unchanged in 20 (60.6%), also with significant difference between the two groups (P = 0.002). SLC is effective in alleviating tamoxifen-induced hot flashes and improving the condition of sleep.
    No preview · Article · Feb 2009 · Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban

  • No preview · Article · Jun 2008 · Zhongguo fei ai za zhi = Chinese journal of lung cancer